Certificate in terms Reg 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ganga Pharmaceuticals has submitted to BSE the quarterly certificate required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate was issued by the company's Registrar and Share Transfer Agent, KFIN Technologies Limited, and confirms the details of shares that were dematerialized or rematerialized during the quarter ended June 30, 2025. Separate confirmations were filed with both CDSL and NSDL, and the data has been furnished to the stock exchanges where the company is listed (BSE, scrip code 539680). The letter is signed by Managing Director Bharat Sharma and is a routine compliance filing with no operational or financial figures disclosed.
This is a standard regulatory compliance submission and does not carry any material impact on the company's business, financials, or share price. Retail investors can treat this as routine housekeeping required by SEBI.